Your browser doesn't support javascript.
loading
Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).
Jódar, Esteban; Michelsen, Marie; Polonsky, William; Réa, Rosangela; Sandberg, Anna; Vilsbøll, Tina; Warren, Mark; Harring, Signe; Ziegler, Uwe; Bain, Stephen.
Affiliation
  • Jódar E; Faculty of Medicine, Universidad Europea de Madrid, Madrid, Spain.
  • Michelsen M; Department of Endocrinology and Nutrition Service, Hospital Universitario QuironSalud Madrid, Madrid, Spain.
  • Polonsky W; Novo Nordisk A/S, Søborg, Denmark.
  • Réa R; Behavioral Diabetes Institute, San Diego, California.
  • Sandberg A; Department of Psychiatry, University of California San Diego, La Jolla, California.
  • Vilsbøll T; Department of Clinical Medicine, SEMPR, Universidade Federal do Paraná, Curitiba, Brazil.
  • Warren M; Novo Nordisk A/S, Søborg, Denmark.
  • Harring S; Steno Diabetes Center Copenhagen, University of Copenhagen, Hellerup, Denmark.
  • Ziegler U; Department of Endocrinology, Physicians East, Greenville, North Carolina.
  • Bain S; Novo Nordisk A/S, Søborg, Denmark.
Diabetes Obes Metab ; 22(8): 1339-1347, 2020 08.
Article in En | MEDLINE | ID: mdl-32227613
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2020 Type: Article